Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects

Trial Profile

An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Bleeding ulcer; Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jan 2018 According to an AstraZeneca media release, the approval was based on D961TC00002 and D961TC00004 trials.
    • 19 Jan 2018 According to an AstraZeneca media release, the MHLW has approved a partial registration change in terms of additional dosage and administration for children aged 1 year and older for Nexium 10 mg and 20 mg Capsules as a PPI indicated for gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis (initial treatment), nonerosive reflux disease, and Zollinger-Ellison syndrome as well as marketing approval for Nexium 10 mg and 20 mg Granules for Suspension, Sachet with the same indication.
    • 08 Jan 2014 Status changed from recruiting to completed, ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top